ATXN2 and amyotrophic lateral sclerosis: A genome-wide CRISPR screen identified v-ATPase as a potential drug target to reduce levels of the ALS protein ataxin-2 (Kim et al., 2022), suggesting that FUSR503fs mutations likely affect the autophagic lysosomal system.